Universität zu Köln

Wuerdemann, Nora, Doescher, Johannes, Laban, Simon ORCID: 0000-0001-6732-7137, Hoffmann, Thomas K. and Klussmann, Jens Peter (2019). Human papillomavirus and oropharyngeal squamous cell carcinoma. Frequently asked questions. Onkologe, 25 (3). S. 224 - 232. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1433-0415

Full text not available from this repository.

Abstract

IntroductionThe human papillomavirus (HPV) belongs to the papillomavirus family. Based on the carcinogenic potential of the virus, it is classified into low-risk and high-risk types. Low-risk types are responsible for the development of genital papillomas and recurrent respiratory papillomatosis, whereas 5% of all carcinomas worldwide are caused by HPV high-risk types. HPV is considered asexually transmitted disease and is not only responsible for the development of anogenital carcinomas but also for asubgroup of HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) in the head and neck area.MethodsThis work is based on aselective literature search in the PubMed database on the subject of HPV-associated OPSCC.ResultsThe OPSCCs are located primarily in the tonsils or base of the tongue and represent atumor entity with asignificantly increasing incidence. Due to virus-driven carcinogenesis, these tumors differ from smoking and alcohol-associated OPSCC in both genetic and molecular biological aspects and are distinguished by asignificantly improved prognosis. HPV-association is confirmed by the expression of the surrogate marker p16, which has been included in the 8th edition of the TNM classification of malignant tumors since 2017. Nevertheless, the choice of treatment is currently not based on HPV status, which leads to ahigh rate of side effects in both entities.ConclusionPrognostic models for risk stratification have been developed in order to enable treatment deintensification for certain patient groups in the future. In order to monitor the course of disease and early detection of treatment failure, current screening and surveillance methods, such as liquid biopsy are being tested. The HPV vaccination, which serves as a primary prophylaxis with respect to tumor development, is recommended by the Standing Vaccination Committee for girls and recently also for boys aged 9-14 years.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Wuerdemann, Nora UNSPECIFIED UNSPECIFIED UNSPECIFIED Doescher, Johannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Laban, Simon UNSPECIFIED orcid.org/0000-0001-6732-7137 UNSPECIFIED Hoffmann, Thomas K. UNSPECIFIED UNSPECIFIED UNSPECIFIED Klussmann, Jens Peter UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-155881
DOI:	10.1007/s00761-018-0519-4
Journal or Publication Title:	Onkologe
Volume:	25
Number:	3
Page Range:	S. 224 - 232
Date:	2019
Publisher:	SPRINGER HEIDELBERG
Place of Publication:	HEIDELBERG
ISSN:	1433-0415
Language:	German
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language ORAL HUMAN-PAPILLOMAVIRUS; 8TH EDITION; HPV INFECTION; HEAD; CANCER; PREVALENCE; RISK; CLASSIFICATION; VACCINATION; EXPRESSION Multiple languages Oncology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/15588